Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion

Author(s)Maria Lopes, MD, MS, Fernando L. Pagan, MD, Bhavesh Shah, RPh, BCOP

This publication was sponsored by Acadia Pharmaceuticals Inc.

This clinical brief provides insights from a panel of stakeholders about Parkinson disease (PD) and the prevalence and care of PD psychosis (PDP). The experts also offer key information about PDP from the payer and clinical perspectives.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Setting Treatment Goals in RA: Remission, Joint Damage, and Systemic Risk

Predicting GLP-1 Discontinuation From Pharmacy Claims

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Setting Treatment Goals in RA: Remission, Joint Damage, and Systemic Risk

Predicting GLP-1 Discontinuation From Pharmacy Claims

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups